Every mature ingredient category moves through the same arc: it starts by competing on amount, then on purity, and eventually on delivery. Omega-3s are now deep into that third phase, and the data from the past year makes the shift easy to see.
The first generation of the category was simple fish oil: win on volume, keep the price down. The second generation was concentration: strip out the bulk, concentrate EPA and DHA, and let potency per capsule do the selling. That shift alone reshaped the economics of the category. According to the Global Organization for EPA and DHA Omega-3s (GOED), concentrates now capture 40.5% of global omega-3 value from just 21.5% of global volume, the clearest evidence yet that the market will pay a real premium for less bulk and more efficacy.
The third generation is where things get more interesting, and it's being driven less by concentration and more by mechanism.
What krill actually proved
Krill oil's performance in GOED's 2026 report is the clearest data point the category has produced on this shift. Krill grew 15.1% in global volume and 13.3% in value in 2025, the fastest growth of any omega-3 source tracked, with demand in China up 53% in a single year. That's not a story about abundant supply or aggressive pricing. Krill is a small, wild-harvested category with real supply constraints. It grew because of what it represents: a phospholipid-bound delivery format that consumers and formulators associate with better absorption.
That's the signal worth taking seriously. Krill didn't win on quantity; it won on the promise that how omega-3 is delivered matters as much as how much is delivered. The category has been waiting for proof that consumers will pay for that idea. Krill provided it.
Where the same report gets more cautious
GOED's own analysis is more measured than the growth headline suggests, and that's worth sitting with. On dose, the report draws a direct line from krill's low EPA+DHA concentration to a real competitive exposure: krill's positioning depends on its delivery story, but its comparatively low EPA+DHA "risks substitution by traditional fish oils" among consumers trying to hit higher intake targets. That's not a marketing knock; it's the industry's own market research body naming the ceiling on krill's dose economics.
On sourcing, the picture is more nuanced than "wild-harvested equals risky." The krill fishery is quota-regulated, and the Marine Stewardship Council has certified it as sustainably managed. But GOED also notes rising public unease about harvesting a species that sits at the base of the Antarctic food web, and points to negative press coverage in Europe that has already led some brands to scale back or discontinue their krill lines. The fishery may be certified sustainable; the harder problem for brands is that consumer perception doesn't always wait for the science to catch up, and GOED itself flags that dynamic as a real drag on the category's growth trajectory going forward.
Krill didn't win on quantity. It won on the promise that how omega-3 is delivered matters as much as how much is delivered. The next question is what happens when that promise isn't limited to a single wild harvest.
Beyond fish, beyond krill
The natural next question is what a phospholipid-delivery story looks like when it isn't tied to one Antarctic fishery with a small number of harvesters and a fixed annual quota. That question is where a new territory is starting to take shape across the ingredient industry, and it's being described, in shorthand, as "beyond krill"—not a rejection of what krill proved, but the next step built on it: phospholipid-bonded omega-3 delivery, engineered rather than harvested.
This is a positioning territory more than a single product, and it's worth watching which suppliers move to claim it. The premise is straightforward: if the delivery mechanism is what's driving consumer willingness to pay, a controlled, scalable manufacturing process should be able to deliver the same mechanism, at a concentration a wild harvest was never going to reach, without the dose ceiling GOED flags as a substitution risk, and without a sustainability narrative that depends on consumer perception holding steady.
Where the ingredient side is heading
Naturmega, an advanced lipid science company, is one developer building directly into this territory. Its Ruby-O® platform, backed by U.S. patents, uses a bio-inspired, phospholipid-bonded architecture built through a bioenzymatic process rather than a wild-catch supply chain. The more interesting detail is that the architecture is designable rather than fixed: the lipid structure can be engineered toward a given application instead of simply replicating what a wild harvest happens to produce. For the company, that's the difference between designing the mechanism and simply harvesting it.
Built on that same platform, Naturmega's SupriaX2™ is the ingredient positioned to lead its entry into the "beyond krill" territory. The headline number is dose: roughly 450mg of combined EPA+DHA per serving, close to two and a half times the 176mg typically delivered by krill oil, directly answering the dose-ceiling risk GOED's own analysis flags. But the more consequential engineering decision sits underneath that number: a higher proportion of EPA+DHA bonded directly to phospholipids, not simply more oil in the capsule. Phospholipids are the lipid form cell membranes are built from, which is why they're regarded as among the most efficient vehicles for carrying lipids across membranes and into cells. A higher ratio of phospholipid-bound EPA+DHA, more than the dose number alone, is the real mechanism upgrade, and it's the detail formulators should be evaluating as closely as the headline claim.
SupriaX2™ is also shellfish-free, sidestepping both the crustacean allergen labelling that applies to krill oil and the sourcing-perception questions raised above. It was launched at Vitafoods Europe 2026. For formulators, the pitch combines several threads at once: the delivery mechanism the market has already validated, at a concentration the market has been asking for, without the allergen or sourcing-perception baggage.
Whether Naturmega ends up defining this territory or simply arrives early to it, the direction is the more important story for brand and ingredient teams to track. The next phase of omega-3 competition looks increasingly like it will be won on designed delivery, not on how much can be harvested, but on how precisely a mechanism can be built.
The editorial takeaway
Fish oil competed on amount. Concentrates competed on purity. Krill proved the market will pay for mechanism, and, in the same breath, GOED's own data shows where that mechanism runs into its limits on dose and on public trust. The next chapter belongs to whoever can deliver that mechanism at scale, by design, rather than at the mercy of a single harvest, and that's the omega-3 story worth following through 2026 and 2027.
The views above reflect the author's editorial analysis of publicly available industry data, including GOED's 2026 Global EPA & DHA Omega-3 Ingredient Market Report. Ingredient suppliers with a delivery-mechanism or formulation story relevant to this piece are welcome to reach out for a follow-up feature.
